The therapeutic effect of Melatonin, Metformin and Vitamin E in patients with non-alcoholic fatty liver disease
- Conditions
- onalcoholic fatty liver disease [NAFLD].Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2016040318124N3
- Lead Sponsor
- Vice chancellor for research, Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Having non-alcoholic fatty liver disease (NAFLD) without other liver diseases.
Exclusion criteria: Alcohol consumption of more than 20 gr per day for women or more than 30 gr in men for at least 3 consecutive months during a recent 5 year period, Patients with autoimmune hepatitis, hepatitis B, hepatitis C and other chronic liver diseases, Patients with heart failure (New York Heart Association class II to IV), Patients taking drugs that cause osteo-hepatitis like fibrates, statins, NSAID, Amiodarone, and Tamoxifen, Patients with proven diabetes mellitus under medical therapy, Patients receiving vitamin C, zinc and selenium or antioxidant agents during a recent three months, Patients with kidney disease and kidney failure or any patients with GFR less than 60.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver function tests. Timepoint: Before treatment and 3 months later. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method ipid tests. Timepoint: Before treatment and 3 months later. Method of measurement: blood sample.;Sugar tests. Timepoint: Before treatment and 3 months later. Method of measurement: blood sample.